Submit Manuscript  

Article Details


Prospects for miR-21 as a Target in the Treatment of Lung Diseases

[ Vol. 27 , Issue. 3 ]

Author(s):

Yan Ding, Yapeng Hou, Yanhong Liu, Xiaoyong Xie, Yong Cui and Hongguang Nie*   Pages 415 - 422 ( 8 )

Abstract:


MicroRNA (miRNA/miR) is a class of small evolutionarily conserved non-coding RNA, which can inhibit the target gene expression at the post-transcriptional level and serve as significant roles in cell differentiation, proliferation, migration and apoptosis. Of note, the aberrant miR-21 has been involved in the generation and development of multiple lung diseases, and identified as a candidate of biomarker, therapeutic target, or indicator of prognosis. MiR-21 relieves acute lung injury via depressing the PTEN/Foxo1-TLR4/NF-κB signaling cascade, whereas promotes lung cancer cell growth, metastasis, and chemo/radio-resistance by decreasing the expression of PTEN and PDCD4 and promoting the PI3K/AKT transduction. The purpose of this review is to elucidate the potential mechanisms of miR-21 associated lung diseases, with an emphasis on its dual regulating effects, which will trigger novel paradigms in molecular therapy.

Keywords:

MiR-21, acute lung injury, asthma, idiopathic pulmonary fibrosis, lung cancer, PI3K/AKT signal pathway.

Affiliation:

Department of Stem Cells and Regenerative Medicine, College of Basic Medical Science, China Medical University, Shenyang, Department of Stem Cells and Regenerative Medicine, College of Basic Medical Science, China Medical University, Shenyang, Department of Stem Cells and Regenerative Medicine, College of Basic Medical Science, China Medical University, Shenyang, Department of Stem Cells and Regenerative Medicine, College of Basic Medical Science, China Medical University, Shenyang, Department of Anesthesiology, the First Affiliated Hospital of China Medical University, Shenyang, Department of Stem Cells and Regenerative Medicine, College of Basic Medical Science, China Medical University, Shenyang



Read Full-Text article